A total grant of over £ 6.5 million has been awarded for seven business-based projects that will focus on the development of therapeutic agents and diagnostics where nanoscale technologies are the focus of innovation.
Grants will be provided by the UK Engineering and Physical Sciences Research Council (EPSRC) and the Technology Strategy Board, and projects will be led by Critical Pharmaceuticals, Johnson Matthey, Molik, Nanomerics, OJ-Bio, Renisha Diagnostics, and Sharp Laboratories. Europe.
The purpose of the investment is to help ensure that the UK can take an early competitive adoption of these technologies and generate early-stage ideas from academics and through the building to generate the healthcare sector around the world They can commercialize them and can face immediate and difficult challenges.
The proposed R&D projects will seek to develop a close relationship between the healthcare community and the emerging nanoscale technology community, evolve rapidly, and commercialize nanoscale technologies at an early stage.
Key challenge areas include preoperative and disease detection and diagnosis, leading to significant improvement in patient outcomes, and effective treatments that are tailored to the needs of patients, and which either modify the underlying disease or potentially Provide treatment.
£ 1 million UK government funding
Separately, a group of projects is to receive more than £ 1 million of UK government funding to enable them to develop new and improved "health-economics" tools or products that provide clinical solutions for infectious agents Provide solutions that will assist and improve design and evaluation. testing.
Funding from the Technology Strategy Board has been provided for three development contracts, in partnership with the UK Department of Health and with additional contributions from the EPSRC to fund educational social science components. These diagnostics for the real world (Europe) will be carried out by the Integrated Medicine and Health Protection Agency.
The funding award follows the Technology Strategy Board and the organizations' participation in the "Organization Assessing the Impact of Evaluation" for development contracts managed by the National Health and Clinical Excellence (NICE) and the National Institute for Health and Clinical Excellence (NICE). Does and has been developed in discussion with the British.
Association of in vitro diagnostics. The competition was organized under the Technology Strategy Board's Infectious Diseases Program aimed at reducing economic burden, death, and such diseases.
Two projects by the Diagnostics for Real World and Health Protection Agency will focus on sexually transmitted infections, while the rest of the integrated medical project will focus on sepsis.
Read More: Skywalkers with BlueTooth